Nanobiotix (NASDAQ:NBTX) Shares Gap Down - Here's Why

Key Points

• Nanobiotix shares opened at $21.22 after closing at $22.78, marking a gap down in the stock price.
• Wall Street analysts have mixed opinions, with two buy ratings, one hold, and one sell rating; the consensus target price is $11.00.
• Institutional investors hold 38.81% of the stock, with Millennium Management recently purchasing 13,452 shares valued at approximately $39,000.

Shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $22.78, but opened at $21.22. Nanobiotix shares last traded at $21.43, with a volume of 38,525 shares.

Wall Street Analyst Weigh In

NBTX has been the subject of a number of research reports. Leerink Partners set a $14.00 target price on shares of Nanobiotix in a report on Thursday, September 18th. HC Wainwright reissued a "buy" rating on shares of Nanobiotix in a report on Friday, September 19th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Nanobiotix in a report on Saturday, September 27th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Nanobiotix has a consensus rating of "Hold" and an average target price of $11.00.

Nanobiotix Stock Down 8.8%

The business's fifty day moving average is $10.60 and its 200-day moving average is $6.42.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nanobiotix stock. Millennium Management LLC purchased a new position in shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 13,452 shares of the company's stock, valued at approximately $39,000. Institutional investors and hedge funds own 38.81% of the company's stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.